**A. Menarini Diagnostics Signs Exclusive Supply and Distribution Agreement with PlexBio**

**Taipei, Taiwan and Florence, Italy – June 24th, 2019** – Taipei-based PlexBio Co., Ltd. and Florence-based A. Menarini Diagnostics, announced they have entered into a supply and distribution agreement for PlexBio’s IntelliPlexTM diagnostic instrument platform and reagent kits for oncology and infectious disease testing. Under the agreement, A. Menarini Diagnostics will be the exclusive distributor for PlexBio’s kits portfolio and manage all marketing, sales and support activities across western Europe, the Middle East and Australia. The aim is to advance both companies’ position in molecular diagnostics with a unique opportunity to expand into new markets and drive future growth.

PlexBio’s IntelliPlexTM instrument platform and Precision Image Code (πCodeTM) MicroDisc technology has enabled the development of a series of high complexity multiplex assays for cost-effective Companion Diagnostic (CDx) testing in cancer management for gene mutations and gene rearrangements. Under the exclusive distribution agreement for the IntelliPlexTM system, PlexBio will enable A. Menarini Diagnostics to offer more personalized health care solutions for optimized treatment outcomes for cancer patients. A. Menarini Diagnostics brings to the partnership its deep and proven experience in expanding IVD markets along the entire value chain and will dedicate sales, customer service, marketing, and support team staff to the commercialization of PlexBio’s product line. Under the agreement, branding under A. Menarini Diagnostics’ label and future collaboration on the development of new applications for liquid biopsy are anticipated.

“Thanks to this agreement Menarini will be able to offer a complete solution in the area of precision oncology,” said Fabio Piazzalunga, General Manager of A. Menarini Diagnostics and President of Menarini Silicon Biosystems. “The IntelliPlexTM product line, in combination with our established CellSearch® and DEPArray™ products for single cells isolation and characterization, will enhance our capability to provide molecular information both from liquid and solid biopsies. We believe that Menarini will play a pivotal role in personalized medicine to support clinicians and, most of all, improve patients’ care”

Dean Tsao, Chairman and Chief Executive of PlexBio said: “We are excited to announce this important partnership with A. Menarini Diagnostics which will provide further momentum for our business. We anticipate both partners will benefit from the natural synergies with several of Menarini’s existing product offerings and, by putting high complexity molecular information at the focus of diagnostic testing, PlexBio and Menarini together will help transform the delivery of care for patients.”

**About A. Menarini Diagnostics:** A. Menarini Diagnostics belongs to the Menarini Pharmaceutical Group which was founded in 1886. Today it is present in 136 countries throughout the world, it counts 17,632 employees and has a 2018 turnover of € 3.6 billion.

For further information, please visit https://www.menarinidiagnostics.com

**Contact Information:**

A. Menarini Diagnostics S.r.l.

Via dei Sette Santi, 3 - 50131

Florence, Italy

Tel. +39. 055. 56801

**About Menarini Silicon Biosystems:**[Menarini Silicon Biosystems](http://www.siliconbiosystems.com), based in Bologna, Italy, and Huntingdon Valley (PA), USA, develops innovative technologies and products that help researchers understand the biological complexity of disease through the study of single cells.

For further information, please visit <https://www.siliconbiosystems.com>

**Contact Information:**

Menarini Silicon Biosystems

Via G. Di Vittorio 21b/3

Castel Maggiore (Bologna)

Tel. +39. 051. 9944100

**About PlexBio Co., Ltd.:** The company established in 2010, designs, develops and manufactures IVD products and instrumentation from its headquarters in Taipei, Taiwan and its affiliate location in Jiangsu Province, China. PlexBio has also established an Innovative Technology Center in South San Francisco, CA, USA. The company is a listed company on the Taiwan emerging stock market (6572:TT).

For further information, please visit <http://www.plexbio.com>

**Contact Information:**

PlexBio, Co., Ltd.

Address: 6F-1, No. 351, Yangguang St., Neihu District, Taipei City 11491, Taiwan

Tel: +886-2-2627-5878

Fax: +886-2-2627-5979

E-mail: contact@plexbio.com